Sara Bay Financial Increases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sara Bay Financial increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 31.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 985 shares of the biopharmaceutical company’s stock after buying an additional 235 shares during the period. Sara Bay Financial’s holdings in Alnylam Pharmaceuticals were worth $232,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $578,000. Toronto Dominion Bank increased its position in shares of Alnylam Pharmaceuticals by 27.3% in the 3rd quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after purchasing an additional 3,315 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Alnylam Pharmaceuticals by 22.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock valued at $20,165,000 after purchasing an additional 13,422 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $7,009,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of recent analyst reports. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $298.61.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock valued at $2,540,455 in the last ninety days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded down $2.89 during mid-day trading on Friday, hitting $246.27. 556,461 shares of the company’s stock traded hands, compared to its average volume of 504,065. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm’s 50 day simple moving average is $246.62 and its 200 day simple moving average is $259.70. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a market cap of $31.76 billion, a PE ratio of -94.00 and a beta of 0.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the company earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.